论文部分内容阅读
当前靶向表面蛋白的疫苗可驱使抗原变异,其结果或是导致更高致病性病毒的出现,或是产生抗原上不同的病毒能逃逸疫苗接种下的控制从而在宿主人群中生存下来。通常的流感疫苗是靶向高度易变的表面蛋白且不能抗异源病毒的攻击。诱导抗流感保守表位的免疫应答的疫苗可提供抗异源病毒攻击的保护作用。作者在此文中报道了用经修饰的痘病毒Ankara(MVA)与腺病毒(Ad)表达核蛋白和基质蛋白(NP+M1)的融合体形成重组体用其接种的
Current vaccines that target surface proteins can drive antigenic variations that either result in the emergence of more virulent viruses or produce antigens that can escape control under vaccination to survive in the host population. The usual influenza vaccines are those that target highly variable surface proteins and are not resistant to heterologous viruses. Vaccines that induce an immune response against a conserved epitope of influenza can provide protection against heterologous viral challenge. Here the authors report that a recombinant was inoculated with a fusion of a modified pox virus Ankara (MVA) and adenovirus (Ad) expressing nucleoprotein and matrix protein (NP + M1)